Adenocarcinoma
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Published in Oncology Business Week, December 9th, 2007
Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, announced updated results from an ongoing Phase 1/2a open-label, dose escalation clinical trial of RAV12, its lead therapeutic antibody in development for the treatment of adenocarcinomas. The objectives of the study were to define the safety profile and maximum tolerated dose of RAV12, to define the pharmacokinetics and describe preliminary efficacy.
"The study results demonstrate that a fractionated dosing regimen allows us to deliver RAV12 with an acceptable level of toxicity, while maintaining exposure that is associated with a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- America's Health Insurance Plans
HSA Plans are Covering Preventive Care on a First-Dollar Basis - American Airlines, Inc.
American Airlines Invites the Public to Join Marlo Thomas and St. Jude Patients to Create One-of-a-Kind Mural to Celebrate 80 Years of Service in the Greater New York Area - American Red Cross, Southeastern Michigan Blood Services Region
Help Save Lives This Holiday Season by Donating Blood - AngioDynamics, Inc.
AngioDynamics to Present at 19th Annual Piper Jaffray Health Care Conference - Angiogenesis
Affitech-Identified Fully Human Anti-VEGF Antibody Candidate is as Effective as Avastin(R) in Preclinical Cancer Models - Angiogenesis
Research Uncovers Molecular Function of Endosialin Target of MORAb-004, Anti-Angiogenic Antibody Being Evaluated for Cancer, Neovascular Disease - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
